Actively Recruiting
Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
Led by Federico Martinón Torres · Updated on 2023-12-26
42000
Participants Needed
1
Research Sites
161 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken. The Galician public health registries will be used for data collection including baseline information and follow-up data. Historical data will be retrieved for comparison purposes. The study aims to observe and analyze data from all the eligible children in Galicia for nirsevimab treatment. The number of eligible children is expected to be approximately 14,000 per each RSV season.
CONDITIONS
Official Title
Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects born in Galicia from April 1st, 2023 to March 1st, 2026
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain, 15707
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here